Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P. Laubach, Paul G. Richardson, Fredrik Schjesvold et al.|The Lancet Oncology|2020Cited by 70
Multiple Myeloma in Russia (First Results of the Registration Trial)Л. П. Менделеева, И Г Рехтина, Naida Baygishieva et al.|Blood|2017Cited by 5
DETERMINATION OF THE COMPONENTS OF THE TECHNICAL PREPARATION OF THE FINALISTS (WOMEN) OF THE 2022 WORLD SAMBO CHAMPIONSHIPV. A. Shemchuk, V. Ya. Susla, R. V. Pavlov et al.|Scientific Journal of National Pedagogical Dragomanov University Series 15 Scientific and pedagogical problems of physical culture (physical culture and sports)|2023Cited by 1
Incidence and Prognostic Value of Bone and Extramedullary Plasmacytomas in Patients with Newly Diagnosed Multiple Myeloma: Data from a Prospective Population-Based StudyM. V. Solovev, M. N. Kozmina, Л. П. Менделеева et al.|Clinical oncohematology|2026Cited by 0